Little Green Pharma has produced a range of Medical Cannabis Oil preparations with differing cannabinoid profiles from different plant varieties. All of our products are relatively low in the psychoactive cannabinoid THC.
Our strictly controlled growing conditions mean we produce the finest product possible – a natural product, without pesticides.
The LGP Classic 10:10 product is available now via Special Access Scheme applications. LGP Classic 10:15 and 20:5 products are soon to be available to patients. The LGP Plus range is undergoing final product testing and will be available late 2018.
LGP Classic Range
This product range is a full plant extract produced locally from Australian grown medicinal cannabis. Our Classic range has a variety of THC and CBD ratios presented in a simple oil formulation. THC and CBD in a 1:1 ratio is a common starting point for practitioners.
LGP Plus Range
This product range is manufactured using a liposomal small-particle oil. Our Plus range of products utilises a unique technology enabling patients to use a micro-dose, which means patients are able to reach a therapeutic dose with much less active ingredients. Our LGP Plus range will be available in late 2018.
LGP Advanced Range
This is LGP’s most exciting product range. The LGP Advanced range utilises a liposomal small-particle oil and very low levels of THC and CBD in a micro-dose, compared to traditional cannabis oils. The advanced range preserves the cannabis resin in it’s most natural state in the final preparation. This means the LGP Advanced range of products will have high levels of CBDA and non-intoxicating THCA. Our LGP Advanced range of products will be available in early 2019.
Want to know more about our cannabis oil products?
For more information about these medical cannabis oil products please download the Patient Information Leaflets or Product Monographs above.
Medical Practitioners can contact our education team at email@example.com or Ph (08) 6280 0050.
There is growing evidence that Medical Cannabis can benefit patients in a variety of clinical settings:
- Chronic Pain
- Multiple Sclerosis
- Palliative care
Our manufacturing breakthrough aims to control the Medical Cannabis particle size encapsulated in the liposomes to optimise the bio-availability so the cannabinoids are readily absorbed into the bloodstream.
results in therapeutic effectiveness being
achieved with low dosage so less cannabis is needed.
More precise control of dosage
gives the medical practitioner better control of the effects of the medicine and helps researchers to more accurately assess the effects in clinical trials.
Full plant cannabinoid profile
our manufacturing process can preserve the full cannabinoid profile found in the source plant – it does not decarboxylate the acid forms of the cannabinoids unless decarboxylation is specifically intended. Research suggests that the full plant profile is important through the “entourage effect”.